Developer of mRNA drugs gets $110M funding boost

11/21/2013 | American City Business Journals · Xconomy

Moderna Therapeutics said it has no intention to go public in the near term after securing $110 million in its latest equity funding round. The Cambridge, Mass.-based firm, which is focused on developing injectable messenger RNA molecules that trigger the body to produce therapeutic proteins, has secured $415 million in funding and development deals to date. The support "will enable us to strike the right balance between urgency and care to build a durable scientific platform and propel the field forward, without the short-term distractions that can side-track a young public company from its mission," Moderna CEO Stephane Bancel said.

View Full Article in:

American City Business Journals · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ